目的:分析全球各国在人工智能辅助药物研发领域的基础研究态势。方法:在Web of Science数据库中检索人工智能辅助药物研发相关论文,采用文献计量学方法分析全球研究趋势及热点,展示各国、各机构产出体量及影响力,分析全球合作态势。结果...目的:分析全球各国在人工智能辅助药物研发领域的基础研究态势。方法:在Web of Science数据库中检索人工智能辅助药物研发相关论文,采用文献计量学方法分析全球研究趋势及热点,展示各国、各机构产出体量及影响力,分析全球合作态势。结果:1970年至今,人工智能辅助药物研发相关科技论文共计6473篇,近10年复合增长率为12.80%。美国论文数量(2228篇)、高被引论文数量(58篇)、总被引频次(108669次)、篇均被引频次(48.77次·篇-1)及国际合作次数(1174次)均排全球首位,8家美国机构进入全球前列。中国论文数量(1534篇)、高被引论文数量(29篇)、总被引频次(34598次)和国际合作次数(671次)仅次于美国,但篇均被引频次(22.55次·篇-1)低于多个国家,4家机构的论文数量进入全球前列。值得注意的是,葛兰素史克公司、辉瑞公司、阿斯利康公司、诺华公司4家制药企业的发文量进入全球前20位。结论:人工智能在药物研发领域的应用发展迅速,高校、科研院所和制药企业共同推进该领域基础研究。美国基础研究实力最强,研究规模大且成果最具影响力。中国论文数量仅次于美国,积累了一定数量的高质量成果,影响力还有待进一步提升。展开更多
Scientific and technological(S&T) competition has become a core and frontier issue in the ongoing China–U.S. strategic competition and the main focus of both countries. Currently, the Biden administration is adop...Scientific and technological(S&T) competition has become a core and frontier issue in the ongoing China–U.S. strategic competition and the main focus of both countries. Currently, the Biden administration is adopting an S&T competition strategy toward China based on the “small yard, high fence” tactical logic, which involves three pillars: investment to make America strong, alignment to get things under control, and competition to weaken China. In the current context of the China–U.S. competition entering a new normal, five inherent contradictions, namely, the gap between strategic expectations and policy effects, shortfall between action capabilities and policy objectives, push-and-pull between strategic deployment and domestic politics, clash between strategic intentions and the S&T innovation ecosystem, and divergences between American priorities and the interests of American allies, will dictate how this administration will implement its S&T competition strategy toward China.展开更多
文摘目的:分析全球各国在人工智能辅助药物研发领域的基础研究态势。方法:在Web of Science数据库中检索人工智能辅助药物研发相关论文,采用文献计量学方法分析全球研究趋势及热点,展示各国、各机构产出体量及影响力,分析全球合作态势。结果:1970年至今,人工智能辅助药物研发相关科技论文共计6473篇,近10年复合增长率为12.80%。美国论文数量(2228篇)、高被引论文数量(58篇)、总被引频次(108669次)、篇均被引频次(48.77次·篇-1)及国际合作次数(1174次)均排全球首位,8家美国机构进入全球前列。中国论文数量(1534篇)、高被引论文数量(29篇)、总被引频次(34598次)和国际合作次数(671次)仅次于美国,但篇均被引频次(22.55次·篇-1)低于多个国家,4家机构的论文数量进入全球前列。值得注意的是,葛兰素史克公司、辉瑞公司、阿斯利康公司、诺华公司4家制药企业的发文量进入全球前20位。结论:人工智能在药物研发领域的应用发展迅速,高校、科研院所和制药企业共同推进该领域基础研究。美国基础研究实力最强,研究规模大且成果最具影响力。中国论文数量仅次于美国,积累了一定数量的高质量成果,影响力还有待进一步提升。
基金the phased result of a key project supported by the National Social Science Fund of China entitled“Research on Cyber Governance Systems from the Perspective of a Holistic Approach to National Security”(17ZDA106).
文摘Scientific and technological(S&T) competition has become a core and frontier issue in the ongoing China–U.S. strategic competition and the main focus of both countries. Currently, the Biden administration is adopting an S&T competition strategy toward China based on the “small yard, high fence” tactical logic, which involves three pillars: investment to make America strong, alignment to get things under control, and competition to weaken China. In the current context of the China–U.S. competition entering a new normal, five inherent contradictions, namely, the gap between strategic expectations and policy effects, shortfall between action capabilities and policy objectives, push-and-pull between strategic deployment and domestic politics, clash between strategic intentions and the S&T innovation ecosystem, and divergences between American priorities and the interests of American allies, will dictate how this administration will implement its S&T competition strategy toward China.
